LXRX

Lexicon Pharmaceuticals, Inc.
CAPPED RATING

Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.

Lexicon Pharmaceuticals, Inc. (LXRX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (D-). The rating has held at C for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -8.6
EV / EBITDA -12.2
Rev Growth YoY -20.7%
Gross Margin 91.4%
Price Return 3M -21.6%
Price Return 12M 16.7%
Catalyst Signal 0.00
Market Cap $810.3M
TTM Revenue $38.5M
Price / Sales 21.0
ROE -43.9%

Historical Factor Score Progression

Held C for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) D- (0.9) B (3.4) C- (2.0) C+ (2.6) C (2.4)
2026-11-06 B- (2.9) F (0.6) B (3.4) C (2.5) C+ (2.7) C (2.4)
2026-10-30 B- (2.9) F (0.6) B (3.4) C+ (2.6) C+ (2.7) C (2.4)
2026-10-23 B- (2.9) F (0.6) B (3.3) C+ (2.7) C+ (2.6) C (2.4)
2026-10-16 B- (2.9) F (0.6) B (3.3) C (2.4) C+ (2.6) C (2.4)
Page 1 of 8
…